#United States #Sugar Land #CAPS #QuVa Pharma #503B Portfolio

QuVa Pharma Acquires 503B Medication Portfolio from CAPS

In a significant development for the pharmaceutical and healthcare industries, QuVa Pharma, Inc. has successfully acquired a portfolio of essential medications from Central Admixture Pharmacy Services, Inc. (CAPS). This acquisition comes on the heels of CAPS' decision to leave the 503B sterile compounding sector, thereby necessitating a smooth transition to maintain the supply of these critical medications to U.S. hospitals.

The agreement was publicly announced on September 8, 2026, with both companies expressing their commitment to ensuring the ongoing availability of vital medical products. Michael Parden, CEO of B. Braun of America, emphasized the importance of this transition. He noted that products such as Cardioplegia, Total Parenteral Nutrition, and Heparin are crucial for patient care, and that this acquisition aids in preserving the continuous supply required by healthcare providers and their patients.

QuVa has established a robust operation with over 200,000 square feet of FDA-registered 503B manufacturing space located in New Jersey and Texas. This also includes 100,000 square feet of distribution centers across Texas and Arizona, effectively positioning QuVa to serve more than 3,500 hospitals and health systems across the nation. Their offerings are noted for meeting rigorous quality standards, which are critical in the healthcare sector.

Stuart Hinchen, CEO of QuVa, highlighted the significance of the acquisition by stating, “We appreciate the opportunity to partner with CAPS to maintain the supply of these critical medications.” Hinchen further elaborated on the challenges faced by healthcare systems in producing medications that are essential for patient care and are often difficult to manufacture reliably at scale. The move exhibits QuVa's dedication to investing in the necessary infrastructure, technologies, and people to support these vital medication categories.

As the rollout of selected products from the acquired portfolio is set to begin later in 2026, QuVa aims to expand its offerings over the subsequent six months. This phased approach will allow healthcare providers to integrate the new products seamlessly into their operations, minimizing any disruption to patient care.

QuVa Pharma, with a keen focus on addressing critical medication needs, operates through two primary businesses. The first supports hospitals by providing essential ready-to-administer and compounded medications, while the second, QuVa BrightStream, connects and normalizes medication data from over 400 source systems across various healthcare sites. This dual approach enables healthcare systems to make data-driven decisions, thereby improving the overall quality of patient care.

The acquisition also reflects a broader trend within the healthcare industry, where partnerships between compounding pharmacies and hospitals are becoming increasingly vital. As hospitals face intense pressures to deliver quality care amidst resource constraints, reliable partnerships can significantly impact their operational efficiency and patient outcomes.

QuVa’s commitment to innovation and quality makes it a trusted partner for health systems as they navigate the complexities of medication management in an ever-evolving healthcare landscape. As healthcare professionals focus on what matters most—their patients—QuVa stands ready to support them with dependable, essential medications.

About QuVa

QuVa continues to set the standard in pharmaceutical services, ensuring that health systems have the medications necessary to provide optimal patient care. By maintaining a strategic focus on quality, infrastructure, and technology, QuVa positions itself as a leader in addressing the critical medication gaps facing hospitals today. For more information about QuVa Pharma and its comprehensive services, visit their official website at onequva.com.

About B. Braun

B. Braun Medical Inc. is recognized for its innovations in smart infusion therapy and pharmacy products, with a steadfast commitment to improving patient outcomes. With a workforce of over 8,500 employees across North America, B. Braun’s extensive reach enhances its ability to contribute to sustainable health solutions. For more insights on B. Braun's services, explore their website.